⌘K
Loading ticker…
As of 2026-08-24, Emergent Biosolutions, Inc. (EBS) has a 3-month relative strength percentile of 10 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 34. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.9%, relative volume 0.62×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
EBS is in a stage 4 downtrend, week 6. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -26.6% / -43.9%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
EBS is held by 28 ETFs as of May 2026. Top owner: AVUV at 0.08% weight, $21M notional. Top 3 carry $30M.
Held by 56 ETFs · $107M across latest filings · largest weight 0.24% (SQLV).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| AVUVAvantis U.S. Small Cap Value ETF | 0.08% | $21M | — |
| FNDA | 0.08% | $7M | — |
| VTWO | 0.01% | $2M | — |
| SCHASchwab U.S. Small-Cap ETF | 0.01% | $2M | — |
| VHTVanguard Health Care ETF | 0.01% | $1M | — |
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| AVSC | 0.03% | $901K | — |
| VFMO | 0.05% | $894K | — |
| GSSC | 0.06% | $620K | −0.04 pp |
| FSCC | 0.17% | $473K | +0.01 pp |
| VTWV | 0.03% | $379K | — |
Showing 10 of 28 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EBS Jan avg: -2.33% median: 1.72% win: 50% σ: 21.76% n: 4 2022-04-12 → 2026-07-31 | EBS Feb avg: 6.41% median: -17.14% win: 25% σ: 59.20% n: 4 2022-04-12 → 2026-07-31 | EBS Mar avg: -17.79% median: -18.99% win: 25% σ: 15.27% n: 4 2022-04-12 → 2026-07-31 | EBS Apr avg: -10.80% median: -14.77% win: 20% σ: 15.03% n: 5 2022-04-12 → 2026-07-31 | EBS May avg: 46.15% median: 10.81% win: 80% σ: 88.19% n: 5 2022-04-12 → 2026-07-31 | EBS Jun avg: -1.44% median: -5.83% win: 40% σ: 12.92% n: 5 2022-04-12 → 2026-07-31 | EBS Jul avg: 13.98% median: -6.40% win: 40% σ: 41.56% n: 5 2022-04-12 → 2026-07-31 | EBS Aug avg: -13.99% median: -31.25% win: 25% σ: 36.80% n: 4 2022-04-12 → 2026-07-31 (current) | EBS Sep avg: -8.34% median: -6.07% win: 50% σ: 15.02% n: 4 2022-04-12 → 2026-07-31 | EBS Oct avg: 2.71% median: 3.94% win: 50% σ: 32.91% n: 4 2022-04-12 → 2026-07-31 | EBS Nov avg: -9.36% median: -4.05% win: 50% σ: 22.99% n: 4 2022-04-12 → 2026-07-31 | EBS Dec avg: 3.32% median: 3.33% win: 50% σ: 9.37% n: 4 2022-04-12 → 2026-07-31 |